



(11) **EP 2 283 020 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
12.12.2012 Bulletin 2012/50

(45) Date of publication and mention
of the grant of the patent:
31.10.2012 Bulletin 2012/44

(21) Application number: **09751280.0**

(22) Date of filing: **18.05.2009**

(51) Int Cl.:
C07D 487/04 ^(2006.01) **A61K 31/519** ^(2006.01)
A61P 35/00 ^(2006.01)

(86) International application number:
PCT/US2009/044325

(87) International publication number:
WO 2009/143051 (26.11.2009 Gazette 2009/48)

(54) **SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES**
SUBSTITUIERTE IMIDAZOPYR- UND IMIDAZOTRIAZINE
IMIDAZOPYRAZINES ET IMIDAZOTRIAZINES SUBSTITUÉES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK TR

(30) Priority: **19.05.2008 US 54345 P**

(43) Date of publication of application:
16.02.2011 Bulletin 2011/07

(73) Proprietor: **OSI Pharmaceuticals, LLC**
Farmingdale, NY 11735 (US)

(72) Inventors:
• **CREW, Andrew, P.**
Farmingdale, NY 11735 (US)
• **JIN, Meizhong**
Farmingdale, NY 11735 (US)
• **KADALBAJOO, Mridula**
Farmingdale, NY 11735 (US)
• **KLEINBERG, Andrew**
Farmingdale, NY 11735 (US)
• **MULVIHILL, Mark, J.**
Farmingdale, NY 11735 (US)
• **WANG, Jing**
Farmingdale, NY 11735 (US)

(74) Representative: **Haile, Alison Victoria et al**
Mintz Levin, Cohn, Ferris, Glovsky and
Popeo IP, LLP
Alder Castle
10 Noble Street
London EC2V 7JX (GB)

(56) References cited:
WO-A-2006/004703 WO-A-2007/075554
US-A1- 2006 046 977

- **MULVIHILL ET AL: "Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 16, no. 3, 23 October 2007 (2007-10-23), pages 1359-1375, XP022453107 ISSN: 0968-0896**
- **KOPECKY D J ET AL: "Identification and optimization of N<3>,N<6>-diaryl-1H-pyrazolo [3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 24, 15 December 2008 (2008-12-15), pages 6352-6356, XP025679027 ISSN: 0960-894X [retrieved on 2008-11-01]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 283 020 B8